Kuboshima Mari, Shimada Hideaki, Liu Tian-Ling, Nomura Fumio, Takiguchi Masaki, Hiwasa Takaki, Ochiai Takenori
Department of Frontier Surgery, Chiba University, Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan.
Cancer Sci. 2006 May;97(5):380-6. doi: 10.1111/j.1349-7006.2006.00192.x.
SEREX has been applied to esophageal SCC, and the TRIM21 gene was identified as a novel SEREX antigen of esophageal SCC. The presence of s-TRIM21-Abs was confirmed by Western blotting using bacterially expressed TRIM21 gene product and was evaluated for clinicopathological significance in patients with esophageal SCC. s-TRIM21-Abs were detected in 18 (20%) of 91 patients with esophageal SCC but not in 42 healthy donors. The presence of s-TRIM21-Abs was partly associated with tumor size (P = 0.063) and poor survival (P = 0.067). To measure serum antibody levels, ELISA using purified recombinant TRIM21 protein was developed. The levels of s-TRIM21-Abs were significantly higher in patients with esophageal SCC than in healthy donors (P = 0.013). s-TRIM21-Abs may be a useful tumor marker to diagnose and predict disease progression in patients with esophageal SCC.
SEREX已应用于食管鳞状细胞癌，TRIM21基因被鉴定为食管鳞状细胞癌的一种新型SEREX抗原。使用细菌表达的TRIM21基因产物通过蛋白质印迹法证实了s-TRIM21抗体的存在，并对食管鳞状细胞癌患者的临床病理意义进行了评估。在91例食管鳞状细胞癌患者中有18例（20%）检测到s-TRIM21抗体，而42名健康供者中未检测到。s-TRIM21抗体的存在与肿瘤大小部分相关（P = 0.063），与生存率低相关（P = 0.067）。为了测量血清抗体水平，开发了使用纯化重组TRIM21蛋白的酶联免疫吸附测定法。食管鳞状细胞癌患者的s-TRIM21抗体水平显著高于健康供者（P = 0.013）。s-TRIM21抗体可能是诊断和预测食管鳞状细胞癌患者疾病进展的有用肿瘤标志物。
